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Introduction
The association between overactive bladder (OAB) and depression was noticed years ago.
The systematic review by Vrijens et al. [1] demonstrated that 26 out of 35 studies indicated the positive association between OAB and depression, while none of the analysed trials showed the negative one. On the one hand, significant deterioration of patient's quality of life caused by OAB symptoms generates stress and thus may lead to the development of mood disorders [2] . On the other hand, depression, which is associated with stress, or taking antidepressant drugs may be a risk factor for new-onset OAB [3, 4] . Frequent co-existance of OAB and depression may also be due to the fact that several common biological pathways are implicated in the pathomechanism of these syndromes. Recent studies by Lai et al. [2] revealed that 27.5% of adult patients (women and men) with OAB had depression, whereas in the clinical trial by Melotti and colleagues [5] , the percentage of women with OAB accompanied by depression was even higherup to 60%. Subjects with depressive disorder present more severe incontinence, and their self-motivation to participate in the behavioural therapy and/or to take the prescribed drugs regularly is significantly lower [2] . Globally, the number of patients concerned by this dual problem is considerable. About 400 million people report urinary urgency and frequency (which are the symptoms of so-called "dry" OAB), and a proportion of them additionally report urgency incontinence (a symptom of so-called "wet" OAB). It has been estimated that even 30-40% of people over 75 suffer from OAB, as the risk of this disease is higher with age [6] . According to the newest report of the World Health Organisation [7] , the total number of people suffering from depression in 2015 exceeded 320 million.
The first-line treatment for OAB are antimuscarinic drugs, whereas depression is usually treated with medicinal products that modulate the monoaminergic (i.e., serotonergic, noradrenergic, or dopaminergic) neurotransmissions. So far, the pharmaceutical market is not able to offer one universal drug that would cure both conditions at the same time, but based J o u r n a l P r e -p r o o f of OAB, imipramine (20 mg/kg, intraperitoneally) significantly reduced signs of urgency [9] .
In fact, this tricyclic antidepressant decreased bladder contractility, increased outlet resistance, and improved urine storage also in humans. A single night-time dose of imipramine (25-150 mg) taken by elderly people with detrusor instability alleviated their lower urinary tract symptoms [10] . Another tricyclic antidepressant, doxepin, prescribed at a dose of 50-75 mg reduced both night-time frequency and night-time episodes of incontinence [11] . The outcomes of our previous experiments demonstrated that inhibition of the CRF1 receptors by SN003 [8, 12] , inhibition of Rho kinase by GSK 269962 [13] , and inhibition of myosin II by blebbistatin [14] improved both cystometric parameters and depressive behaviour in an animal model of DO and depression.
In view of the above, the goal of our present experiments was to determine whether a 14-day administration of solifenacin, mirabegron, or duloxetine would reverse DO and depressionlike signs in rats subjected to corticosterone treatment. DO co-exists with OAB: ca. 64% of patients suffering from OAB have DO, and 83% of patients presenting DO have symptoms of OAB [15] . Solifenacin acts as a competitive antagonist of muscarinic receptors, and it is indicated as the first-line drug in the treatment of OAB. Solifenacin inhibits acetylocholine activity on autonomic nerve endings and thus, it decreases bladder motility, enhances bladder capacity as well as it reduces contractions and urgency of urination [16] . Mirabegron is a selective agonist of β3-adrenergic receptors, and it is usually used as the second-line therapy in patients with OAB. Stimulation of the β3-adrenoceptors in the bladder leads to bladder relaxation, increased urine storage, reduced bladder contraction, and diminished unwanted urinations [17] . As for duloxetine, it belongs to the serotonin norepinephrine reuptake inhibitors (SNRIs), and though primarily approved for treatment of depression and generalized anxiety disorder, this drug is also prescribed for stress urinary incontinence.
J o u r n a l P r e -p r o o f 5 Additionally, we decided to check the effects of the tested drugs on the hippocampus, prefrontal cortex, Barrington's nucleus, urinary bladder, and urine levels of Interleukin 1β (Il-1β), CRF, brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), and tumour necrosis factor α (TNF-α). All of these biomarkers are involved in nerve growth or inflammation and they are related to both DO and depression. Since OAB as well as depression are more frequently diagnosed in women than in men [5] [6] [7] , the experiments were carried out in female rats.
Materials and methods
This study was carried out in accordance with binding Polish and European law related to the experimental studies on animal models. The protocol was approved by the Local Ethics Committee in Lublin, Poland (licence no. 21/2017).
Animals
96 female Wistar rats were used in the experiments. Their initial weight was 200-225 g. The tested rats were kept in metabolic cages in environmentally controlled rooms (temperature of 22-23 ºC, natural light/dark cycle, relative humidity ca. 45-55%) with ad libitum access to water and food. The animals were experimentally naïve, tested only once, and they were assigned to one of the following treatment groups that received: 
Drugs
For the first 14 days of the experiments the animals received subcutaneous (s.c.) injections of corticosterone (Tocris) and then, they were given solifenacin (Astellas Pharma, Tokyo, Japan), mirabegron (Astellas Pharma, Tokyo, Japan), or duloxetine (Eli Lilly, Indianapolis, 
Surgical procedures
The surgical procedures were carried out in the same way as had been previously described [21] . The abdominal wall was opened with a vertical midline incision of approximately 10 mm. A double lumen catheter was inserted through the apex of the bladder dome and fixed with a 6-0 suture. In the same session the carotid artery was cannulated. To prevent an infection of the urinary tract, 100 mg of cefazolin sodium hydrate (Biofazolin, Sandoz) was given s.c. All the surgical procedures were performed under anaesthesia with an i.p. injection of ketamine hydrochloride (75 mg/kg; Ketanest, Pfizer) and xylazine (15 mg/kg; Sedazin, Biowet). Rats were laid down supine on a warm mattress (37 ºC). A sufficient depth of anaesthesia was measured by lack of spontaneous movement and lack of withdrawal response to noxious toe pinch.
Conscious cystometry
Cystometric measurements were carried out 17 days after the surgical procedures (i.e. 3 days after the last injection of the tested drugs) in the same way as had been previously described [12] . The bladder catheter was connected via a three-way stopcock to a pressure transducer (FT03; Grass Instruments) and to a microinjection pump (CMA 100; Microject, Solna, Sweden). Cystometry was performed by slowly filling the bladder with physiological saline at a constant rate 0.05 ml/min to elicit repetitive voiding. Micturition volumes were measured by means of a fluid collector attached to a force displacement transducer (FT03C; Grass Instruments). The measurements in each animal represent the average of five bladder micturition cycles after obtaining repetitive voiding. The following cystometric parameters J o u r n a l P r e -p r o o f 7 and relaxation time (RT; s). The clinical meaning of these parameters have been described previously [12] .
Behavioural studies
The behavioural studies were carried out 72 h after the last injection of solifenacin, mirabegron, or duloxetine.
Forced swim test
The FST was carried out in accordance with the method elaborated by Porsolt et al. [22] . At first, the pre-test was performed. Each animal was put individually into a dedicated glass cylinder (diameter 25 cm, height 65 cm) filled with water (temperature of 23-25 ºC) and it stayed there for 15 min. After 24 h, the standard test was carried out. It was performed under identical conditions as the pre-test but it lasted for 5 min. An animal was judged immobile when it remained floating passively, performing only slow movements to keep its head above the water.
Locomotor activity
The spontaneous locomotor activity was measured in an Optical Animal Activity Monitoring System (Digiscan apparatus; Omnitech Electronics, Columbus, OH, USA). The activity score was recorded as an interruption of the infrared light beam by a tested animal. 1-h horizontal activity was assessed. Before the standard analysis, a 15-min habituation period was introduced.
Biochemical analyses
After the cystometric and behavioural studies, the animals were killed by decapitation and their brains and urinary bladder tissue were collected. The following parameters were measured in the hippocampus, prefrontal cortex, Barrington's nucleus, urinary bladder, and urine of the tested rats: Interleukin 1-β (ELISA Kit for IL1b, Cloud-Clone, USA), brainderived neurotrophic factor (BDNF Emax ® ImmunoAssay System PROMEGA, USA), corticotropin releasing factor (Mouse/Rat CRF-HS ELISA Kit, Alpco, Salem, NH, USA), nerve growth factor (Rat NGF ELISA Kit, LifeSpan BioSciences, USA), and tumor necrosis factor α (ELISA Kit for TNF Alpha, LifeSpan BioSciences, USA). Preparation of the samples as well as the measurements were performed according to the manufacturers' instructions. The statistical measurements were carried out using two-way analysis of variance (ANOVA) followed by Bonferroni's post hoc test. The obtained results were presented as the means ± standard error of the mean (SEM). A difference between the tested groups was considered as statistically significant when p < 0.05.
Results

Forced swim test
As was presented in Fig. 2A , after the 14-day administration of corticosterone (20 kg/mg/day) the tested rats were significantly more immobile than the vehicle-treated group. The depressogenic-like effect was reversed only by the 14-day therapy with duloxetine (1 mg/kg/day). Neither solifenacin (0.03 mg/kg/day) nor mirabegron (1 mg/kg/day) reversed the corticosterone-induced effects. Two-way ANOVA demonstrated a significant corticosteroneduloxetine interaction [F(1,44) = 36.52; p < 0.0001] with a significant effect of corticosterone [F(1,44) = 16.12; p = 0.0002] and a significant effect of duloxetine [F(1,44) = 12.94; p = 0.0008]. The interactions between corticosterone and solifenacin or mirabegron were not considered as significant [F(1,42) = 4.00; p = 0.0521 for corticosterone-solifenacin; F(1,44) = 3.01; p = 0.0900]. The swimming pattern of rats that received only solifenacin, mirabegron, or duloxetine for 14 days was comparable to the one observed for the control group.
Locomotor activity
None of the tested drugs given alone or in respective combinations influenced the locomotor activity of animals ( Fig. 2B ).
Cystometric study
The 14-day pretreatment with corticosterone (20 mg/kg/day) resulted in considerable changes in several cystometric parameters. A significant increase in ANVC, DOI, and FNVC, accompanied by a significant decrease in BC and ICI were recorded. The values of BCD, MVP, PVR, and RT were not significantly influenced by either of the administered agents. As was summarised in Table 1 , the 14-day treatment with solifenacin (0.03 mg/kg/day) did not manage to reverse the corticosterone-induced cystometric changes specific to DO. 
Biochemical study
Neither solifenacin (0.03 mg/kg/day) nor mirabegron (1 mg/kg/day) or duloxetine (1 mg/kg/day) when given for 14 days to the vehicle-treated animals affected levels of IL1-β, CRF, BDNF, NGF, and TNF-α.
Interleukin 1β levels
As suspected, the 14-day corticosterone therapy (20 mg/kg/day) significantly increased levels of IL1-β in the hippocampus (by ca. 22% vs. control group), prefrontal cortex (by ca. 22%), and the Barrington's nucleus (by ca. 29%). It did not change IL1-β values in the urinary bladder and urine ( Fig. 3 ). Neither solifenacin (0.03 mg/kg/day) nor mirabegron (1 mg/kg/day) when given for 14 days reversed the effects of corticosterone. However, the duloxetine treatment (1 mg/kg/day given for 14 days) normalized concentrations of IL1-β in the tested brain areas of animals exposed to corticosterone. Two-way ANOVA revealed 
Tumor necrosis factor α levels
Rats exposed to the 14-day administration of corticosterone (20 mg/kg/day) presented considerably raised levels of TNF-α in the hippocampus (by ca. 25% vs. the vehicle-treated group), prefrontal cortex (by 23%), and the Barrington's nucleus (by ca. 32%). TNF-α levels in the urinary bladder and urine were not significantly changed ( Fig. 7) . Neither solifenacin (0.03 mg/kg/day) nor mirabegron (1 mg/kg/day) when given for 14 days normalized the TNFα values in the tested brain areas. However, the 14-day duloxetine treatment (1 mg/kg/day) reversed all noxious changes in TNF-α levels induced by corticosterone exposure. Two-way J o u r n a l P r e -p r o o f whether a given agent has a potential to be used in OAB accompanied by depressive symptoms. This model significantly responded to both oxybutynin chloride (a standard antimuscarinic drug) and conventional antidepressants, like imipramine and fluoxetine [12] .
As expected, after the 14-day exposure to corticosterone, the tested animals presented the depressive-like behaviour in the FST and the signs of DO easily assessed in the cystometric studies. Their ANVC, DOI, and FNVC values were significantly elevated, whereas the BC and ICI levels were decreased. Additionally, corticosterone-treated rats presented signs of [27, 28] . It has been found out that IL-1β and TNF-α partially influence synthesis and metabolism of serotonin, by stimulation of indoleamine 2,3dioxygenase (i.e., an enzyme involved in tryptofan metabolism) [29] and by activation of the serotonin transporter SERT [30] . The pro-inflammatory cytokines activate the HPA axis and promote CRF secretion [23] . In our studies we also detected significant abnormalities in the CRF system. Corticosterone administration considerably increased CRF levels in the bladder, urine, and the brain areas involved in voiding control and development of depression, i.e. the amygdala, hippocampus, prefrontal cortex, and Barrington's nucleus. The CRF system seems to be one of the most essential common denominators that link depression and OAB.
Disturbances in the CRF system are observed in depressed patients [31] [32] [33] and they play a significant role in urinary bladder overactivity [34] . Increased CRF levels in CSF were detected in suicide victims [35] and subjects with depression [31, 32, 36] . Elevated CRF levels may lower the micturition threshold, micturition volume, and intercontraction intervals, whereas the blockage of the CRF system by their antagonists results in reduced DO in animal models [37] . Corticosterone-treated rats also presented decreased levels of BDNF and NGF in the brain and urinary bladder samples along with their elevated levels in urine. Similarly to our result, urinary BDNF and NGF levels are higher in patients with OAB [38] . It seems that Journal Pre-proof J o u r n a l P r e -p r o o f 13 abnormalities in urinary BDNF is a more sensitive marker of OAB than NFG in subjects without other disorders of the lower urinary tracts [39] . By contrast, elevated levels of BDNF and NGF were detected in the brains of depressed people and suicide victims [40] , which also was in line with our outcomes.
Results of the present study demonstrated that both solifenacin and mirabegron act mainly via peripheral pathways in OAB. Though an acute administration of solifenacin (0.03 mg/kg) and mirabegron (1 mg/kg) reversed the symptoms of DO [8] , the 3-day post-treatment interval applied in our prolonged study abolished these effects. Only a partial decrease of the elevated ameliorated anhedonia-like behaviour in animals subjected to the chronic unpredictable mild stress [41] . On the other hand, an agonist of β3-adrenergic receptorsamibegron (0.3-3.0 mg/kg/day, i.p. for 14 days), reduced immobility of the Flinders Sensitive Line rats in the FST [43] and it exerted positive effects in the chronic mild stress model of depression in mice (3mg/kg/day, i.p. for 33 days) [42] .
Interestingly enough, the 3-day post-treatment interval did not abolish solifenacin and mirabegron effects on normalisation of the neurotrophin levels. Introduced treatment elevated the reduced BDNF levels in the urinary bladder and diminished the increased BDNF levels in urine. Moreover, solifenacin and mirabegron reversed the corticosterone-induced abnormalities of NGF values in the hippocampus, amygdala, urinary bladder, and urine. Liu et al. [44] suggested that urinary NGF could be an indicator of effectiveness of antimuscarinic treatment. Improvement of OAB symptoms due to tolterodine therapy was accompanied by a J o u r n a l P r e -p r o o f significant drop in urinary NGF levels, whereas failure with solifenacine treatment did not influence NGF values in urine [45] . Our result did not confirm this concept, as quite normalised urinary NGF levels in solifenacin-treated rats were accompanied by only partially reversed changes in DO symptoms.
We confirmed the suppositions of Thor and Katofiasc [46] that the central pathways are responsible for the inhibitory effects of duloxetine on the activity of the bladder detrusor, since the positive effects of this SNRI on cystometric parameters were noted even 72 h after discontinuation of the treatment. Normalisation of DOI levels is particularly encouraging, since DOI is regarded as a more precise parameter describing bladder contraction than BC, BP, ICI, MVP, ANVC, or FNVC. Its increase allows to determine the intensity of DO [21, 47] . Another encouraging observation from our study was the fact that the 14-day administration of duloxetine did not influence PVR, though urinary retention can be observed after SNRIs [48] . Furthermore, Solmaz et al. [4] demonstrated that antidepressant drugs (including escitalopram, sertraline, fluoxetine, paroxetine, or venlafaxine) may increase the prevalence of OAB and intensify its symptoms. But in experiments by Schwen and colleagues [49] , an intravenous administration of duloxetine (3 mg/kg) increased bladder capacity and inhibited bladder overactivity induced by 0.25% solution of acetic acid. Two i.p. doses of duloxetine (2 mg/kg) prolonged the first void latency, reduced a number of urine spots, and reduced the urine volume in the OAB model in mice [9] . Similarly, in a randomised placebocontrolled clinical trial, Steer et al. [50] demonstrated that the treatment with duloxetine (given at a dose of 80 mg/day for 4 weeks and then elevated to 120 mg/day for 8 weeks) had a better therapeutic efficacy than placebo in women with OAB symptoms. It significantly decreased both the number of voiding episodes and the number of urinary incontinence episodes, and prolonged the daytime voiding interval. Rezze et al. [18] reported that duloxetine reduced postmicturition residual volume when compared to placebo-treated patients. Duloxetine elevates levels of serotonin and noradrenalin, but its affinity towards serotonin and noradrenaline receptors is not clinically significant. According to the literature data [18] effectiveness of duloxetine in the stress urinary incontinence is due to blockage of the reuptake of serotonin and noradrenaline at the presynaptic motoneurons in the Onuf's nucleus. The Onuf's nucleus is located in the sacral segments of the spinal cord. It consists of motoneurons that control the contracting activity of the urethal sphincter. By elevation of serotonin and noradrenaline levels, duloxetine allows continuous stimulation of the α1adrenoceptors and serotonergic receptors at the post-synaptic side, which in turn activates the glutamatergic transmission and facilitates contraction of the urethal sphincter. Additionally, J o u r n a l P r e -p r o o f the direct serotonergic inhibition on sensory afferents, which results in decreased bladder activity also contributes to the observed effects [51] . Mechanisms responsible for duloxetine effects on the bladder capacity are also controlled at the spinal level, and they are dependent on the non-selective serotonergic pathways [18] .
Duloxetine normalized CRF, cytokines, BDNF, and NGF levels in all tested samples, which was not surprising. Antidepressant drugs are known to have an inhibitory effect on the upregulated CRF system [52] , and the elevated CRF values in CSF are at least partially reduced after antidepressant treatment [53] [54] [55] . Interferon-α-induced depression, associated with elevated levels of pro-inflammatory cytokines, was successfully treated by antidepressants [56, 57] . Similarly, lower levels of BDNF and NGF are increased as a consequence of antidepressant treatment [58, 59] . The outcomes of the present study are generally in line with observations of Wang et al. [19] who reported the first case of an effective duloxetine therapy in a female patient with OAB and depression, who had not responded to citalopram and had experienced side effects due to fluoxetine and imipramine treatment. After several months of taking duloxetine (up to 60 mg/kg), both depression and OAB symptoms improved.
In summary, we found out that the corticosterone-induced model of DO and depression is accompanied by: (1) increased brain levels of the pro-inflammatory cytokines, such as IL-1β and TNF-α, (2) elevated brain, bladder, and urine values of CRF, (3) reduced brain and bladder levels of neurotrophins, like BDNF and NGF, and (4) increased urine values of BDNF and NGF. We also demonstrated that solifenacin and mirabegron act mainly via peripheral pathways, whereas the central pathways are responsible for effects of duloxetine on both depression and DO. 72 hours after discontinuation of duloxetine treatment, its beneficial effects were still detectable. Duloxetine seems to have a potential to become a new treatment option for patients with OAB co-existing with depression. Table 1 Influence of the 14-day intravenous administration of solifenacin (0.03 mg/kg/day), mirabegron (1 mg/kg/day), and duloxetine (1 mg/kg/day) on on the cystometric parameters in conscious rats subjected to corticosterone therapy Corticosterone (CORT, 20 mg/kg/day) was given subcutaneously for 14 days and solifenacin (0.03 mg/kg/day), mirabegron (1 mg/kg/day), or duloxetine (1 mg/kg/day) were administered intravenously for 14-days. The values represent the mean + SEM (n = 10-12 mice per group). The obtained data were assessed by the two-way analysis of variance (ANOVA) followed by Bonferroni's post hoc test. *p < 0.05, ***p < 0.001 versus saline, ^p < 0.05, ^^p < 0.01, ^^^p < 0.001 versus CORT. 
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